Please assess the completion status of the following clinical trial:

Trial Title: Expanded PrEP Implementation in Communities in NSW

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV negative at enrolment, with a negative HIV test result documented within seven days of initiating PrEP~* At high and ongoing risk for acquiring HIV infection through sexual exposure (as defined by Behavioural Eligibility criteria presented in Appendix II and online Risk Assessment Questionnaire in Appendix III), OR previously a PrELUDE study participant~* Aged 18 years or over~* Live in NSW or ACT or visit NSW or ACT enough to attend clinics for follow-up assessments~* Willing and able to provide informed consent~* Medicare ineligible individuals may be enrolled if the clinical service is able to cover the costs of monitoring of the patient~Exclusion Criteria:~* HIV-1 infected or has symptoms consistent with acute viral infection (If HIV positive status is not confirmed by testing, delay starting PrEP for at least one month and reconfirm negative HIV-1 status).~* Having an estimated creatinine clearance (glomerular filtration rate \[GFR\]) \<60ml/min~* Having or developing clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity (including nausea, vomiting, unusual or unexpected stomach discomfort, and weakness)~* Concurrently taking a nephrotoxic agent (e.g., high-dose non-steroidal anti-inflammatory drugs / NSAIDs)~* Allergic to TDF and/or FTC (based on self-report or recorded)~* Concurrently taking prescribed products containing FTC or TDF including ATRIPLA®, COMPLERA®, EMTRIVA, STRIBILD®, VIREAD, TAF (tenofovir alafenamide), GENVOYA, DESCOVY; other drugs containing lamivudine; HEPSERA~* Factors or conditions that may compromise a participant's access to health services for follow-up (incarceration or planned relocation and potential absence from NSW or ACT).~Behavioural eligibility criteria as per NSW PrEP guidelines.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- treatment (Type: EXPERIMENTAL): A single open-label arm. All participants receive daily oral pill containing TDF/FTC

Based on this trial design, predict the completion outcome and termination type (if applicable).